This from “Trader Dealer” website. It shows Consensus Recommendation as Outperform and a Target Price $1.97. Ah! So many high price targets, yet so little movement.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%